Disposition of orally administered cefpodoxime proxetil in foals and adult horses and minimum inhibitory concentration of the drug against common bacterial pathogens of horses

American Journal of Veterinary Research

Volumn 66, Issue 1, 2005, Pages 30-35

  Carrillo, Natalie A ^a   Giguère, Steeve ^a   Gronwall, Ronald R ^a   Brown, Murray P ^a   Merritt, Kelly A ^a   O'Kelley, Jeffrey J ^a  

^a University of Florida College of Veterinary Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFPODOXIME PROXETIL;

ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; ESCHERICHIA COLI; FEMALE; GROWTH INHIBITION; HORSE; KLEBSIELLA; MALE; MINIMUM INHIBITORY CONCENTRATION; NASOGASTRIC TUBE; NEWBORN; NONHUMAN; PASTEURELLA; SALMONELLA ENTERICA; SINGLE DRUG DOSE; SUSPENSION;

ADMINISTRATION, ORAL; AGE FACTORS; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIA; CEFTIZOXIME; FEMALE; HALF-LIFE; HORSE DISEASES; HORSES; MALE; MICROBIAL SENSITIVITY TESTS;

ANIMALIA; BACTERIA (MICROORGANISMS); EQUIDAE; EQUUS CABALLUS; ESCHERICHIA COLI; KLEBSIELLA; PASTEURELLA; SALMONELLA ENTERICA; STREPTOCOCCUS;

EID: 13444301297     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.30     Document Type: Article

References (34)

1. Gayle JM, Cohen ND, Chaffin MK. Factors associated with survival in septicemic foals: 65 cases (1988-1995). J Vet Intern Med 1998;12:140-146.
2. Marsh PS, Palmer JE. Bacterial isolates from blood and their susceptibility patterns in critically ill foals: 543 cases (1991-1998). J Am Vet Med Assoc 2001;218:1608-1610.
3. Wilson WD, Madigan JE. Comparison of bacteriologic culture of blood and necropsy specimens for determining the cause of foal septicemia: 47 cases (1978-1987). J Am Vet Med Assoc 1989; 195:1759-1763.
4. Brewer BD. Neonatal infection. In: Koterba AM, Drummond WH, Kosch PC, eds. Equine clinical neonatology. Philadelphia: Lea & Fibeger, 1990;295-316.
5. Moore RM, Schneider RK, Kowalski J, et al. Antimicrobial susceptibility of bacterial isolates from 233 horses with musculoskeletal infection during 1979-1989. Equine Vet J 1992;24:450-456.
6. Giguère S, Sweeney RW, Bélanger M. Pharmacokinetics of enrofloxacin in adult horses and concentration of the drug in serum, body fluids, and endometrial tissues after repeated intragastrically administered doses. Am J Vet Res 1996;57:1025-1030.
7. Davenport CL, Boston RC, Richardson DW. Effects of enrofloxacin and magnesium deficiency on matrix metabolism in equine articular cartilage. Am J Vet Res 2001;62:160-166.
8. Vivrette S, Bostian A, Bermingham E, et al. Quinolone induced arthropathy in neonatal foals, in Proceedings. 47th Annu Conv Am Assoc Equine Pract 2001;376-377.
9. Brown MP, Gronwall R, Kroll WR, et al. Ampicillin trihydrate in foals: serum concentrations and clearance after a single oral dose. Equine Vet J 1984;16:371-373.
10. Duffee NE, Christensen JM, Craig AM. The pharmacokinetics of cefadroxil in the foal. J Vet Pharmacol Ther 1989;12:322-326.
11. Duffee NE, Stang BE, Schaeffer DJ. The pharmacokinetics of cefadroxil over a range of oral doses and animal ages in the foal. J Vet Pharmacol Ther 1997;20:427-433.
12. Henry MM, Morris DD, Lakritz J, et al. Pharmacokinetics of cephradine in neonatal foals after single oral dosing. Equine Vet J 1992;24:242-243.
13. Frampton JE, Brogden RN, Langtry HD, et al. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992;44:889-917.
14. Backhouse C, Wade A, Williamson P, et al. Multiple dose pharmacokinetics of cefpodoxime in young adult and elderly patients. J Antimicrob Chemother 1990;26(suppl E):29-34.
15. Borin MT, Hughes GS, Patel RK, et al. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil. J Clin Pharmacol 1991; 31:1137-1145.
16. Tremblay D, Dupront A, Ho C, et al. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. J Antimicrob Chemother 1990;26(suppl E):21-28.
17. Ricketts SW. Technique of paracentesis abdominis (peritoneal tap) in the horse. Equine Vet J 1983;15:288-289.
18. Borin MT, Hughes GS, Spillers CR, et al. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil. Antimicrob Agents Chemother 1990; 34:1094-1099.
19. Naber KG, Kinzig M, Adam D, et al. Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue. Infection 1991;19:30-35.
20. Caceci MS, Cacheris WP. Fitting curves to data. Bytes 1984;9:340-362.
21. Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D, eds. Pharmacokinetics. 2nd ed. New York: Marcel-Dekker Inc, 1982; 409-417.
22. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standards. NCCLS document M31-A. Wayne, Pa: National Committee for Clinical Laboratory Standards, 1999.
23. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, twelfth informational supplement; approved standards. NCCLS document M100-S12. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2002.
24. Fujii R, Meguro H, Arimasu O, et al. Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields. Jpn J Antibiot 1989;42:1439-1455.
25. Hughes GS, Heald DL, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther 1989;46:674-685.
26. Saathoff N, Lode H, Neider K, et al. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother 1992;36:796-800.
27. Sanchez LC, Lester GD, Merritt AM. Effect of ranitidine on intragastric pH in clinically normal neonatal foals. J Am Vet Med Assoc 1998;212:1407-1412.
28. Murray MJ, Schusser GF. Measurement of 24-h gastric pH using an indwelling pH electrode in horses unfed, fed and treated with ranitidine. Equine Vet J 1993;25:417-421.
29. Jacks S, Giguère S, Nguyen A. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. Antimicrob Agents Chemother 2003;47:1742-1745.
30. Auckenthaler R. Pharmacokinetics and pharmacodynamics of oral beta-lactam antibiotics as a two-dimensional approach to their efficacy. J Antimicrob Chemother 2002;50(suppl): 13-17.
31. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22.
32. Ringger NC, Pearson EG, Gronwall R, et al. Pharmacokinetics of ceftriaxone in healthy horses. Equine Vet J 1996;28:476-479.
33. Gardner SY, Aucoin DP. Pharmacokinetics of ceftriaxone in mares. J Vet Pharmacol Ther 1994;17:155-156.
34. Guglick MA, MacAllister CG, Clarke CR, et al. Pharmacokinetics of cefepime and comparison with those of ceftiofur in horses. Am J Vet Res 1998;59:458-463.